Table 3 |
|||||||
|
Clinical outcomes 0–12 months |
|||||||
|
Item |
N |
0 months |
12 months |
0 months vs. 12 months |
|||
|
|
|||||||
|
Mean (SD) |
Mean (SD) |
P-value |
Median difference (95%-CI)* |
Improved |
SRM |
||
|
|
|||||||
|
Disease Score (0–10) |
155 |
5.95 (1.74) |
2.31 (2.29) |
p < 0.001 |
4.00 (3.50 to 4.50) |
88% |
1.52 |
|
Symptom Score (0–10) |
184 |
5.74 (1.81) |
3.04 (2.16) |
p < 0.001 |
2.97 (2.50 to 3.25) |
83% |
1.05 |
|
SF-36 scales (0–100) |
|||||||
|
-Physical Function |
161 |
77.09 (24.07) |
84.41 (20.69) |
p < 0.001 |
7.50 (5.00 to 10.00) |
60% |
0.37 |
|
-Role Physical |
157 |
55.47 (38.39) |
72.29 (36.64) |
p < 0.001 |
25.00 (12.50 to 37.50) |
46% |
0.42 |
|
-Role-Emotional |
157 |
68.15 (37.43) |
81.63 (31.98) |
p < 0.001 |
33.33 (16.67 to 33.34) |
39% |
0.33 |
|
-Social Functioning |
161 |
67.93 (25.07) |
77.10 (23.06) |
p < 0.001 |
12.50 (6.25 to 18.75) |
52% |
0.34 |
|
-Mental Health |
160 |
58.74 (18.25) |
66.10 (18.34) |
p < 0.001 |
8.00 (4.00 to 10.00) |
63% |
0.43 |
|
-Bodily Pain |
161 |
59.89 (27.62) |
71.27 (26.76) |
p < 0.001 |
15.50 (9.50 to 21.00) |
54% |
0.38 |
|
-Vitality |
160 |
42.53 (18.34) |
52.84 (18.49) |
p < 0.001 |
12.50 (10.00 to 17.50) |
60% |
0.53 |
|
-General Health |
161 |
53.10 (19.30) |
61.01 (19.48) |
p < 0.001 |
8.50 (5.00 to 11.00) |
63% |
0.45 |
|
SF-36 Health Change (1–5**) |
159 |
3.27 (1.08) |
2.14 (1.02) |
p < 0.001 |
1.50 (1.00 to 2.00) |
65% |
0.71 |
|
SF-36 Physical Component |
154 |
44.01 (10.92) |
47.99 (10.43) |
p < 0.001 |
3.97 (2.71 to 5.30) |
73% |
0.42 |
|
SF-36 Mental Component |
154 |
42.34 (11.98) |
46.84 (10.47) |
p < 0.001 |
3.98 (2.30 to 5.71) |
64% |
0.40 |
|
KINDL subscales (0–100) |
|||||||
|
-Psychic |
16 |
69.75 (19.91) |
69.74 (21.57) |
p = 0.782 |
1.13 (-4.55 to 5.68) |
56% |
0.00 |
|
-Somatic |
16 |
71.18 (17.21) |
71.74 (19.88) |
p = 0.520 |
2.78 (-4.16 to 8.33) |
63% |
0.03 |
|
-Social |
16 |
74.30 (14.89) |
69.73 (18.78) |
p = 0.292 |
-4.16 (-9.72 to 3.65) |
31% |
-0.26 |
|
-Function |
15 |
67.42 (12.08) |
69.18 (14.45) |
p = 0.367 |
2.04 (-3.41 to 6.82) |
67% |
0.20 |
|
KINDL Summary Score (0–100) |
16 |
70.39 (17.67) |
69.77 (17.91) |
p = 0.889 |
0.31 (-4.02 to 4.93) |
50% |
-0.06 |
|
KITA subscales (0–100) |
|||||||
|
-Psychosoma |
31 |
62.23 (19.76) |
76.44 (13.62) |
p = 0.001 |
13.54 (4.17 to 21.87) |
77% |
0.62 |
|
-Daily Life |
29 |
63.22 (12.40) |
67.96 (15.43) |
p = 0.038 |
6.25 (0.00 to 12.50) |
55% |
0.28 |
|
|
|||||||
|
*Positive differences indicate improvement. Improved: Percentage of patients improved from baseline. **1 = "much better now than one year ago", 5 = "much worse now than one year ago". SRM: Standardised Response Mean effect size (small: 0.20–0.49, medium: 0.50–0.79, large: ≥ 0.80). |
|||||||
|
Hamre et al. BMC Complementary and Alternative Medicine 2007 7:10 doi:10.1186/1472-6882-7-10 |
|||||||
